Navigation Links
Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Date:5/7/2009

- 1Q09 Xyrem(R) net sales of $18 million are 56% higher than 1Q08

- 1Q09 operating expenses of $29 million are 50% lower than 1Q08

PALO ALTO, Calif., May 7 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the quarter ended March 31, 2009. Total revenues for the first quarter of 2009 were $22.1 million, compared to $14.6 million for the first quarter of 2008. Xyrem(R) (sodium oxybate) oral solution net sales for the first quarter of 2009 were $17.7 million, an increase of 56% over net sales of $11.3 million for the first quarter of 2008. This increase reflects the effect of significant price increases over the past twelve months and sales volume growth. Net sales of once-daily Luvox CR(R) (fluvoxamine maleate) Extended Release Capsules were $3.6 million for the first quarter of 2009.

Jazz Pharmaceuticals' cash and cash equivalents as of March 31, 2009 were $17.0 million. On March 31, 2009, Jazz Pharmaceuticals did not pay $5.1 million in interest due to the holders of the $119.5 million principal amount of its senior secured notes due June 2011, and Jazz Pharmaceuticals remains in default on the notes. The total overdue interest due on the notes through March 31, 2009 is $9.6 million.

"Our focus for the remainder of 2009 will be on increasing sales of our commercial products for their approved indications and submitting the NDA (New Drug Application) for JZP-6, our sodium oxybate product currently in Phase III clinical trials for the treatment of fibromyalgia," said Bruce Cozadd, Chairman and Chief Executive Officer. "We are pleased to report that we have completed the second pivotal trial for JZP-6 and expect to announce the results in mid-2009. We remain on track to submit our NDA for JZP-6 by the end of the year," he continued. '/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 CarePoint ... Radiologists, Amish P. Patel, MD, and Sujoy Menon, ... welcomes Dr. Patel and Dr. Menon to the ... array of diagnostic imaging services to patients in ... Medical Center, Christ Hospital and Hoboken University Medical ...
(Date:8/21/2014)... 21, 2014Popular fiction that normalizes and glamorizes violence against ... be associated with a greater risk of potentially harmful ... new study are presented in the article " Fiction ... in Adolescent and Young Adult Females ," published in ... from Mary Ann Liebert, Inc., publishers . The ...
(Date:8/21/2014)... have developed a genetically engineered line of mice that ... on epilepsy, Alzheimer,s and other diseases. , The ... of fluorescence in response to different calcium levels. This ... and microglia, to be studied in a new way. ... how the brain works," said Petr Tvrdik, Ph.D., ...
(Date:8/21/2014)... August, 21, 2014 Young girls with an ... may be at increased risk of developing urinary tract ... Baptist Medical Center. The treatment may be as simple ... bubble baths and swimming pools. , "Vulvitis is a ... said senior author Steve J. Hodges, M.D., associate professor ...
(Date:8/21/2014)... with schizophrenia often have trouble engaging in daily tasks ... from San Francisco State University suggests the reason might ... required to complete tasks. , The research, detailed in ... of Abnormal Psychology , can assist health professionals in ... those patients function normally by breaking up larger, complex ...
Breaking Medicine News(10 mins):Health News:Two Top Radiologists Join CarePoint Health 2Health News:Women's health and Fifty Shades: Increased risks for young adult readers? 2Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:Researchers identify potential risk factors for urinary tract infections in young girls 2Health News:Difficulty assessing effort drives motivation deficits in schizophrenia, study finds 2
... 24 NHS Choices ( http://www.nhs.uk ), the,digital ... well guide on women,s,health aged 18-39 aimed at ... lifestyle., Based on NHS accredited information, the ... with information about,walking to get healthy, looking after ...
... June 24 TransUnion announced today a ... cycle workflow and,financial analytics product suite -- ... Institute (ANI) Healthcare Financing Conference. Revenue,Manager is ... real time,patient eligibility for financial assistance at ...
... LOS ANGELES, June 24 Anti-Doping Research,Inc. (ADR), one ... performance-enhancing drugs in sport, is pleased to announce that ... "We,ve been up and running and fully-operational for a ... Officer of the organization. "But,now it,s all official and ...
... Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical ... today, in an update for Company,shareholders, said its ... 31, 2008,totaled $32,300., Net income for the ... Company announced that patient billings from its four ...
... To, Implement Electronic Bill / Payment Solutions Before Minnesota,s ... ... and CONCORD, Calif., June 24 More than one,hundred auto insurance ... Mitchell Medical,s 2008 Industry,Conference held March 17-19 in Monterey, CA were ...
... in Generic Market Information Offers Newport Horizon ... ... SHANGHAI, China, June 24 /Xinhua-PRNewswire/ -- Thomson Reuters, the,world,s leading ... CPhI China 2008(1) the release of Newport,Horizon Premium, designed specifically ...
Cached Medicine News:Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 2Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 3Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 4Health News:Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 3Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 4Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 2Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 3
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe customer ... , Managing Partner and Healthcare Industry Group Leader, has ... which recognizes the most inspiring people in the life-sciences ... in research and development, marketing, technology, creativity, strategy and ... 2006 as a partner in its leading Rosetta Consulting ...
(Date:8/21/2014)... 2014 /CNW/ - Eisai Limited is pleased to support the ... comic book available in Canada . The ... to educate children and their parents about epilepsy, the most ... more than 300,000 Canadians. Eisai is guided by a corporate ... which the patient is central – there was a need ...
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance (CEA) ... series designed to educate children about the most common neurological ... Medikidz Explain Epilepsy comic series tells a fictional story ... middle school while living with epilepsy. "Despite ... is still so much misinformation and lack of awareness out ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Administration (FDA) has accepted for review the Company,s supplemental ... Use for the prevention of gout flares in patients ... Fee Act (PDUFA), the goal for a standard review ...
... CITY, Nev., Nov. 22, 2011   Denali Concrete Management ... November 21, 2011 of the reverse acquisition of Denali ... of which Denali acquired all the outstanding shares of ... has been granted from Can-Fite an exclusive license over ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: